This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The Zacks Analyst Blog Highlights: Chewy, Pinterest, Schlumberger, EOG Resources and Moderna
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Chewy, Pinterest, Schlumberger, EOG Resources and Moderna
Moderna ETFs to Shine Bright on Booster Update, New Study Data
by Sweta Jaiswal, FRM
Moderna is expected to gain on approval for booster shots and new positive data on its COVID-19 vaccine.
6 Stocks to Buy on the Dip With Strong Upside Left for 2021
by Nalak Das
We have narrowed down our search to six large-cap stocks that have attained a 52-week high this year but are currently trading at a sharp discount. These are: CHWY, PINS, ROKU, SLB, EOG and MRNA.
mRNA COVID-19 Vaccine Makers Lose Steam After Strong Rally
by Indrajit Bandyopadhyay
Stocks of mRNA-based COVID-19 vaccine makers, MRNA, PFE and BNTX fall for two consecutive days on bearish sentiments after a strong rally as well as probable side-effects of their vaccines.
Do Options Traders Know Something About Moderna (MRNA) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Moderna (MRNA) stock based on the movements in the options market lately.
Perrigo (PRGO) Q2 Earnings Lag, Sales Hurt by Weak Cold Season
by Zacks Equity Research
Perrigo (PRGO) reports dismal second-quarter 2021 results. Stock down.
Is Moderna (MRNA) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (MRNA) Outperforming Other Medical Stocks This Year?
Is iShares MSCI USA Equal Weighted ETF (EUSA) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for EUSA
Novavax's (NVAX) Q2 Loss Widens, Revenues Miss, Shares Down
by Zacks Equity Research
Novavax (NVAX) reports wider-than-expected loss in the second quarter of 2021 while revenues also miss estimates. Shares down in after-hours trading.
Stock Market News for Aug 6, 2021
by Zacks Equity Research
Benchmarks ended in the green on Thursday, as investors accessed positive weekly jobless claims data and awaited the monthly jobs report on Aug 6.
Bull of the Day: Vertex Pharmaceuticals (VRTX)
by Kevin Cook
Scientific innovation in the treatment of cystic fibrosis bolsters success and pipeline confidence
Moderna (MRNA) Q2 Earnings Top, COVID-19 Vaccine Brings $4.2B
by Zacks Equity Research
Moderna's (MRNA) COVID-19 vaccine continues to enjoy robust demand. The company delivered 199 million doses of its COVID-19 vaccine during the second quarter.
Stock Market News for Aug 5, 2021
by Zacks Equity Research
The Dow and the S&P 500 closed in the red on Wednesday weighed by a lower-than-expected private-sector jobs report and Fed's Vice Chairman Richard Clarida's comment on higher interest rates in 2023 given the current path of economic recovery.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Moderna (MRNA) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Moderna (MRNA) delivered earnings and revenue surprises of 7.49% and 1.45%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Athira (ATHA) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus to be on the company's pipeline progress, mainly on its small molecule candidate ATH-1017 for Alzheimer's disease, on Athira's (ATHA) second-quarter earnings call.
Is a Surprise Coming for Moderna (MRNA) This Earnings Season?
by Zacks Equity Research
Moderna (MRNA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Drug/Biotech Stocks Q2 Earnings Due on Aug 5: REGN, MRNA, ZTS, ILMN
by Zacks Equity Research
Let us take a look at what is in store for some of the drug/biotech stocks, which are scheduled to report on Aug 5.
Stock Market News for Aug 4, 2021
by Zacks Equity Research
Benchmarks closed in the positive territory on Tuesday, as investors ignored the rise in new cases of the delta variant, and instead focused more on the upbeat second-quarter earnings results.
Delta Variant Surge Brings Biotech ETFs in Focus
by Sweta Jaiswal, FRM
The biotech sector seems like a lucrative investment space as the delta variant of coronavirus continues to spread.
Ocugen (OCGN) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Ocugen (OCGN) is likely to provide updates related to regulatory progress of its COVID-19 vaccine, Covaxin, in the United States when it reports second-quarter 2021 results.
Is a Beat Likely for Moderna (MRNA) This Earnings Season?
by Zacks Equity Research
Investors are likely to focus on any updated outlook for Moderna's (MRNA) authorized coronavirus vaccine, on the second-quarter earrings call.
Intellia (NTLA) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on updates on pipeline candidates, especially NTLA-2001, when Intellia (NTLA) reports second-quarter earnings.
What's in Store for Amgen (AMGN) This Earnings Season?
by Zacks Equity Research
Volume growth from Amgen's (AMGN) key drugs like Prolia, Otezla Repatha and other and biosimilars portfolio is expected to have been partially offset by biosimilar/generic competition for mature drugs.
Eli Lilly (LLY) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Higher demand for its growth drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) second-quarter sales.